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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S288progression among medication users in the Osteoarthritis Initiative (OAI)
to identify interventions or pathways that may be of interest for future
clinical trials.
Methods: An exploratory analysis was conducted using OAI participants
with annual medication inventory form data between baseline and the 36-
month (mo) follow-up visit (n ¼ 2,938). Consistent medication users were
deﬁned for each medication classiﬁcation (class) as a participant reporting
at every annual visit that they were regularly using an oral prescription
medication at the time of the clinic visit. Two deﬁnitions of consistent
medication nonuserwere assessed: 1) deﬁnite nonuser: participants never
reported the prescription medication, and 2) probable nonuser: partici-
pants never reported regularly using an oral prescriptionmedication at the
time of the clinic visit. The exploratory analysis focused on medication
classes with  40 users. Key outcome measures were 12-mo quantitative
joint space width at x ¼ 0.250 (JSW250), JSW250 change (12-mo to 36-mo
visits), 12-mo WOMAC pain score, and WOMAC pain score change (12-mo
to 36-mo visits). Change was calculated as follow-up minus baseline. Each
medication class was analyzed separately. We explored ﬁve sets of
comparisons including threewith nonusers matched to users based on OAI
cohort, race, gender, age ( 5 years), and body mass index ( 5 kg/m2): 1)
no matching: users to all deﬁnite nonusers, 2) matched: users to deﬁnite
nonusers, 3) matched and restricted to only participants with JSW250
data: users to deﬁnite nonusers, 4) no matching: users to all probable
nonusers, and 5) matched: users to probable nonusers. A Cohen effect size
was generated for each medication class in each set of comparisons (d¼
[user mean-nonuser mean] divided by pooled standard deviation).
Medication classes with 4 out of 5 effect sizes for JSW250 change > 0.10 or
< -0.10 for WOMAC pain change were further explored with box plots to
determine if the median change of matched deﬁnite nonusers was beyond
interquartile range (IQR) of users.
Results: Twenty-six medication classes were eligible for screening (Table
1). Table 1 contains sample sizes and effect sizes for each medication class.
Anti-estrogen, anticonvulsants, antineoplastic agents, progestogens, anti-
depressants, hypoglycemics, and ACE inhibitors were further explored
with box plots for JSW250 change. Anti-estrogen users’ IQR included less
JSW250 change than the median for nonusers. Progestogens also had
a potential signal but the other medications had clear overlap between
users and nonusers. For symptommodiﬁcation, alpha-adrenergic blockers
and diuretics were further explored with box plots of WOMAC pain
change. Alpha-adrenergic users’ IQR included greater improvement in
WOMAC pain scores than the median for nonusers but diuretic users and
nonusers had clear overlap.
Conclusions: A hormonal pathway, theoretically associated with bone
turnover, may be an area for further focus since anti-estrogen and
progestogen users had evidence of slower JSW change while bisphosph-
onate users had greater JSW change. Furthermore, weak but consistent
evidence suggested that central nervous system agents may deserve
further research since anticonvulsants and antidepressant users had
slower JSW changewhile anxiolytics users had greater JSW change. Alpha-
adrenergic users had signal for improved symptoms but no other medi-
cations had complimentary signals.
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Purpose: To quantify changes to articular cartilage in patients following
viscosupplementation therapy with mild to moderate osteoarthritis using
T1r MRI.
Methods: Following IRB guidelines, 10 subjects (mean age, 56  10 yrs)
with Kellgren-Lawrence Grades 1 and 2 OA, and who never had prior VS or
knee surgery, were scanned at baseline, 6 weeks post-, and 3 months post-
VS using Hylan G-F 20 (3T, Siemens Medical Solutions, Malvern, PA). T1-
weighted isotropic MPRAGE images were acquired for segmentation of
cartilage, and T1r-weighted 3D TrueFISP imageswere acquired to calculate
spatial T1r relaxation maps. Sixteen T1r-weighted slices were acquired in
each aspect to allow for volumetric analysis. Image acquisition parameters
have been described previously. Isotropic sagittal MPRAGE images were
re-sliced along coronal and axial views and interpolated to match the
resolution of T1r- weighted images. Inter- and intra-scan motion was
corrected 3D rigid-body co-registration algorithms (Analyze, AnalyzeDir-
ect, Inc., KS). Femoral and tibial images were co-registered separately due
to discrepancies in ﬂexion angle between imaging sessions. ROI analysis
was performed on the same locations for three time points to accurately
quantify changes in T1r through mean compartmental analysis and
percent change maps from baseline images. Cartilage was segmented
using the SliceOMatic (Tomovision, Quebec, CA) software package. Co-
registered T1r-weighted images were ﬁt pixelwise to the linearized,
mono-exponential signal decay equation ln(S) ¼ -TSL/T1r + ln(S0). Volu-
metric T1r means were calculated by layer depth (superﬁcial, middle,
deep) as well as by region (medial and lateral patella, femoral condyles,
and tibial plateau). Statistical analysis was performed using a one-tailed
paired t-test between time points. Additional data to be analyzed but not
present for this abstract include the visual analog pain, WOMAC, and IKDC
subjective scores before injection and at the time of follow-up MRI.
WORMS scoring for each patient is currently being performed and will be
correlated to quantitative ﬁndings. Statistical signiﬁcance was accepted
when p<0.05.
There were signiﬁcant differences in volumetric T1r scores in both the
medial and lateral compartments of the superﬁcial patella (p< 0.05) 6
weeks following but not after three months (Med. - p<0.1, Lat. - p 20%
across the entire patella while Figure 2 has no signiﬁcant difference in
average between two following time points. There is a large region across
the middle of the lateral facet with an average T1r score < 20% versus the
volumetric mean. This trend of non-uniform spatial changes to T1r
following VS regiments is prevalent among all patients.
Conclusions: These data suggest that VS has a quantiﬁable physiolog-
ical effect on knee articular cartilage. This effect is greater in the
superﬁcial layers than in the deep layers. Intuitively, direct contact
between VS and cartilage occurs at the superﬁcial layer, and there may
be a subsequent physical mechanism of action for VS. Interestingly, the
greatest effects were observed in the patella-femoral compartment
which may be due to lower load-bearing activities and increased
cartilage thickness. Future work will assess methods to predict homo-
or heterogeneous changes within the articular cartilage through
correlation analysis with WORMS, WOMAC, and other qualitative
assessments. While some patients responded positively to the VS, as
calculated through lower T1r scores, there were some who did not or
had higher T1r values. There may be both placebo effects as well as
anti-inﬂammatory mechanisms associated with the VS which allowed
patients to push through pain more than before thereby causing
increased damage to the cartilage tissue.
